Comis R L
Semin Oncol. 1986 Sep;13(3 Suppl 3):40-4.
Etoposide is one of the most active drugs used in the treatment of small-cell lung cancer (SCLC). Recently, studies were completed that evaluated the substitution of etoposide for doxorubicin (Adriamycin) used in combination with cyclophosphamide and vincristine. This study has shown that equivalent antitumor activity, as measured by objective response, can be obtained with the combination of cyclophosphamide, etoposide, and vincristine (CEV) as compared with the CAV combination. A longer response duration and median survival are seen in extensive-disease patients treated with the CEV combination. As expected, no cardiotoxicity is associated with CEV therapy, and interestingly, there is no potentiating neurotoxicity with CEV. A study recently completed has shown that CEV can be effectively combined with intensive radiation therapy to the chest administered simultaneously. CEV appears to be an effective alternative to CAV, and it can be readily combined with aggressive radiation therapy.
依托泊苷是治疗小细胞肺癌（SCLC）最有效的药物之一。最近，完成了一些研究，评估用依托泊苷替代与环磷酰胺和长春新碱联合使用的阿霉素（多柔比星）的效果。这项研究表明，与环磷酰胺、阿霉素和长春新碱（CAV）联合用药相比，环磷酰胺、依托泊苷和长春新碱（CEV）联合用药在客观缓解率方面可获得同等的抗肿瘤活性。在接受CEV联合治疗的广泛期疾病患者中，缓解持续时间更长，中位生存期也更长。正如预期的那样，CEV治疗未出现心脏毒性，有趣的是，CEV也没有增强神经毒性。最近完成的一项研究表明，CEV可与胸部同步强化放射治疗有效联合。CEV似乎是CAV的有效替代方案，并且它可以很容易地与积极的放射治疗联合使用。
